Advent International to acquire a significant stake in Suven Pharmaceuticals
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
Allam was serving recently as the CEO at Public Investment Fund
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
The investment will enable the company to enter European markets as well as enhance margins in current markets
The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha
Aster DM Healthcare and Faruk Medical City will jointly provide training and academic support to medical and paramedical staff
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Subscribe To Our Newsletter & Stay Updated